Julia K. Tietze - Concepedia

Author

Julia K. Tietze

Ludwig-Maximilians-Universität München ORCID

Also Known As

J TIETZE, J Tietze, J. K. Tietze, J. Tietze, J.K. Tietze, Julia Katharina Tietze, Julia K Tietze, Julia K. Tietze, Julia Katharina Tietze, Julia Tietze

105

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

Ludwig-Maximilians-Universität München LMU Klinikum Heidelberg University German Cancer Research Center University Hospital Heidelberg

About

Julia K. Tietze is an author at Ludwig-Maximilians-Universität München specializing in medicine, dermatology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	2K
2	Cell Biology	2	2	198
3	Health Sciences	1	1	55
4	Allergy	1	1	82
5	Clinical Immunology	1	1	116

Julia K. Tietze

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy Lars Hofmann, Andrea Forschner, Carmen Loquai, European Journal of Cancer UrologyHepatologyAnti-pd-1 TherapyGastrointestinal PharmacologyLiver Physiology	2016	638
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy Lisa Zimmer, Simone M. Goldinger, Lars Hofmann, European Journal of Cancer Translational MedicineHeart FailureCardiovascular DiseaseAnti-pd-1 TherapyMedicine	2016	552
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition Markus V. Heppt, Lucie Heinzerling, Katharina C. Kähler, European Journal of Cancer Prognostic FactorsProgrammed Cell Death-1MedicineMelanomaImmunology	2017	196
CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis Lisa Ann Gerdes, Kathrin Held, Eduardo Beltrán, Annals of Neurology Clinical ImmunologyLymphocyte DevelopmentImmunologyImmune RegulationPathology	2016	116
Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma Markus V. Heppt, Alexander Roesch, Benjamin Weide, European Journal of Cancer Prognostic FactorsMucosal MelanomaSurgical OncologyGastrointestinal OncologyMedicine	2017	97
Delineation of antigen-specific and antigen-nonspecific CD8+ memory T-cell responses after cytokine-based cancer immunotherapy Julia K. Tietze, Danice Wilkins, Gail D. Sckisel, Blood	2012	90
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients Teresa Amaral, Felix Kiecker, Sarah Schaefer, Journal for ImmunoTherapy of Cancer	2020	86
Characterization of mouse CD4 T cell subsets defined by expression of KLRG1 Niklas Beyersdorf, Xin Ding, Julia K. Tietze, European Journal of Immunology Klrg1 ExpressionAutoimmune DiseaseAllergyAdaptive Immune SystemMedicine	2007	82
Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma Akiko Arakawa, Sigrid Vollmer, Julia K. Tietze, Frontiers in Immunology	2019	82
Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis Markus V. Heppt, Thomas Eigentler, Katharina C. Kähler, Cancer Immunology Immunotherapy Concurrent ElectrochemotherapyCancer ImmunosurveillanceMedicineMelanomaImmunology	2016	80

Page 1